The Department of Justice accused Biotheranostics of submitting and causing the submission of false claims to Medicare for Breast Cancer Index tests. The department alleged Biotheranostics promoted and performed the tests when they weren’t needed to diagnose and treat breast cancer.
The DOJ claimed Biotheranostics ordered the tests for patients who hadn’t been in remission for five years and who hadn’t been taking the breast cancer treatment tamoxifen. Based on clinical practice guidelines, the tests were not reasonable and necessary, according to the department.
While Biotheranostics agreed to pay the settlement, it’s not a determination of liability.
More articles on legal and regulatory issues:
Tenet beats class-action lawsuit stemming from kickback investigation: 6 things to know
Jury convicts KentuckyOne Health physician on 1 count of healthcare fraud over unnecessary pacemakers
Man who dressed as Spider-Man to wash windows at pediatric hospital sentenced to 105 years for child pornography
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
